Hypericin Induces Apoptosis in MDA-MB-175-VII Cells in Lower Dose Compared to MDA-MB-231

被引:1
作者
Gamasaee, Niusha Abbasi [1 ]
Radmansouri, Maryam [1 ]
Ghiasvand, Saeedeh [2 ]
Shahriari, Fatemeh [3 ]
Marzouni, Hadi Zare [4 ]
Aryan, Hoda [5 ,6 ]
Jangholi, Ehsan [6 ,7 ]
Javidi, Mohammad Amin [1 ,3 ,8 ]
机构
[1] Islamic Azad Univ, Fac Adv Sci & Technol, Pharmaceut Sci Branch, Dept Mol & Cellular Sci, Tehran, Iran
[2] Malayer Univ, Fac Sci, Dept Biol, Malayer, Iran
[3] Tarbiat Modares Univ, Fac Biol Sci, Dept Mol Genet, Tehran, Iran
[4] Mashhad Univ Med Sci, Student Res Comm, Mashhad, Iran
[5] Islamic Azad Univ, Tehran Med Sci Branch, Young Researchers & Elite Club, Tehran, Iran
[6] Islamic Azad Univ, Tehran Med Sci Branch, MSSA, Tehran, Iran
[7] Islamic Azad Univ, Tehran Med Sci Branch, Amir Almomenin Hosp, Clin Res Dev Ctr, Tehran, Iran
[8] ACECR, Breast Canc Res Ctr, Canc Alternat & Complementary Med Dept, Tehran, Iran
关键词
Anticancer drug; Hypericin; MDA-MB-175-VII; MDA-MB-231; P53 wild type; BREAST-CANCER; STEM-CELLS; P53; INHIBITION; RECEPTOR; THERAPY; IMPACT;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Breast cancer is the major cause of death from cancer among women around the world. Given the drug resistance in the treatment of this disease, it is very important to identify new therapies and anticancer drugs. Many studies demonstrated that hypericin could induce apoptosis in different cancer cell lines; however, the underlying mechanism is not well understood yet. Therefore, this study aimed to evaluate the anticancer effect of hypericin in two breast cancer cell lines, one with wild type P53 and the other with mutant P53. Methods: In this study, the MDA-MB-231 and MDA-MB-175-VII cell lines were treated with different concentrations of hypericin for 24 and 48 hours. The measurement of cell death was performed by MTT assay. The cell apoptosis rate was measured using annexin V/propidium iodide assay through flow cytometry. The level of expression in P21 and P53 genes was evaluated by real time PCR. Immunocytochemistry (ICC) analysis was performed for P21 (direct target for P53 protein) to confirm the results. Results: The results showed that hypericin could have dose-dependent cytotoxic effects on the MDA-MB-231 and MDA-MB-175VII cell lines, and its cytotoxicity is much higher in the latter cells. According to flow cytometry results, 86% of MDA-MB-175-VII cells underwent apoptosis with IC50 dose of hypericin for MDA-MB-231 cells after 24 hours. Moreover, after 24 hours of exposure to hypericin with MDA- MB-231 IC50 concentration, the expression of P53 and P21 genes upregulated in MDA-MB-175-VII much more than MDA-MB-231 when both cell lines were treated with 24 hours IC50 dose of MDA-MB-231. The ICC analysis on P21 confirmed that by treating both cell lines with MDA-MB-231 IC50 dose of hypericin for 24 hours, this protein is overexpressed much more in MDA-MB-175-VII cells. Conclusion: The results of this study demonstrated that hypericin's apoptotic and cytotoxic effects on cancer cells may be mediated via P53 overexpression, cell cycle arrest and the subsequent apoptosis. Therefore, it is of great importance to consider that hypericin would have better impact on cells or tumors with wild type P53.
引用
收藏
页码:387 / 392
页数:6
相关论文
共 34 条
[21]   Cytotoxic and apoptogenic effect of hypericin, the bioactive component of Hypericum perforatum on the MCF-7 human breast cancer cell line [J].
Mirmalek, Seyed Abbas ;
Azizi, Mohammad Amin ;
Jangholi, Ehsan ;
Yadollah-Damavandi, Soheila ;
Javidi, Mohammad Amin ;
Parsa, Yekta ;
Parsa, Tina ;
Salimi-Tabatabaee, Seyed Alireza ;
Kolagar, Hossein Ghasemzadeh ;
Alizadeh-Navaei, Reza .
CANCER CELL INTERNATIONAL, 2016, 16
[22]   Cytotoxic effects of hyperatomarin, a prenylated phloroglucinol from Hypericum annulatum Moris subsp annulatum, in a panel of malignant cell tines [J].
Momekov, G. ;
Ferdinandov, D. ;
Zheleva-Dimitrova, D. ;
Nedialkov, P. ;
Girreser, U. ;
Kitanov, G. .
PHYTOMEDICINE, 2008, 15 (11) :1010-1015
[23]   Catalytic inhibition of human DNA topoisomerase IIα by hypericin, a naphthodianthrone from St. John's wort (Hypericum perforatum) [J].
Peebles, KA ;
Baker, RK ;
Kurz, EU ;
Schneider, BJ ;
Kroll, DJ .
BIOCHEMICAL PHARMACOLOGY, 2001, 62 (08) :1059-1070
[24]   Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy [J].
Prat, Aleix ;
Fan, Cheng ;
Fernandez, Aranzazu ;
Hoadley, Katherine A. ;
Martinello, Rossella ;
Vidal, Maria ;
Viladot, Margarita ;
Pineda, Estela ;
Arance, Ana ;
Munoz, Montserrat ;
Pare, Laia ;
Cheang, Maggie C. U. ;
Adamo, Barbara ;
Perou, Charles M. .
BMC MEDICINE, 2015, 13
[25]   Mammographic Breast Density Is Associated With the Development of Contralateral Breast Cancer [J].
Raghavendra, Akshara ;
Sinha, Arup K. ;
Le-Petross, Huong T. ;
Garg, Naveen ;
Hsu, Limin ;
Patangan, Modesto, Jr. ;
Bevers, Therese Bartholomew ;
Shen, Yu ;
Banu, Arun ;
Tripathy, Debu ;
Bedrosian, Isabelle ;
Barcenas, Carlos H. .
CANCER, 2017, 123 (11) :1935-1940
[26]   Cytotoxic activity of Hypericum perforatum L. on K562 erythroleukemic cells:: Differential effects between methanolic extract and hypericin [J].
Roscetti, G ;
Franzese, O ;
Comandini, A ;
Bonmassar, E .
PHYTOTHERAPY RESEARCH, 2004, 18 (01) :66-72
[27]   Herbal Medicine as Inducers of Apoptosis in Cancer Treatment [J].
Safarzadeh, Elham ;
Shotorbani, Siamak Sandoghchian ;
Baradaran, Behzad .
ADVANCED PHARMACEUTICAL BULLETIN, 2014, 4 :421-427
[28]   Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer [J].
Schiavon, Gaia ;
Hrebien, Sarah ;
Garcia-Murillas, Isaac ;
Cutts, Rosalind J. ;
Pearson, Alex ;
Tarazona, Noelia ;
Fenwick, Kerry ;
Kozarewa, Iwanka ;
Lopez-Knowles, Elena ;
Ribas, Ricardo ;
Nerurkar, Ashutosh ;
Osin, Peter ;
Chandarlapaty, Sarat ;
Martin, Lesley-Ann ;
Dowsett, Mitch ;
Smith, Ian E. ;
Turner, Nicholas C. .
SCIENCE TRANSLATIONAL MEDICINE, 2015, 7 (313)
[29]  
Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI [10.3322/caac.21654, 10.3322/caac.20006, 10.3322/caac.21332, 10.3322/caac.21254, 10.3322/caac.21601, 10.3322/caac.20073, 10.3322/caac.21387, 10.3322/caac.21551]
[30]   Cross-talk between estradiol receptor and EGFR/IGF-IR signaling pathways in estrogen-responsive breast cancers: Focus on the role and impact of proteoglycans [J].
Skandalis, Spyros S. ;
Afratis, Nikolaos ;
Smirlaki, Gianna ;
Nikitovic, Dragana ;
Theocharis, Achilleas D. ;
Tzanakakis, George N. ;
Karamanos, Nikos K. .
MATRIX BIOLOGY, 2014, 35 :182-193